Psych-STRATA Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness
- Coordinator
- Universitaet Muenster, Germany
- Runs
- 1 October 2022 to 30 September 2027
- Status
- Running
- EU funding
- €10.3m
- Total cost
- €10.3m
- Partners
- 31 organisations in 14 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057454
What the project is doing
In the project's own words, from its summary on CORDIS.
A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy. However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach. This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines.
It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. PSYCH-STRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD.
These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response. Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitaet Muenster | Muenster | Germany | Coordinator |
| The University of Adelaide | Adelaide | Australia | Associatedpartner |
| Global Alliance of Mental Illness Advocacy Networks Europe Aisbl | Bruxelles / Brussel | Belgium | Participant |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| World Psychiatric Association | Thonex | Switzerland | Associatedpartner |
| Novamechanics Limited | Nicosia | Cyprus | Third party |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| European Research Services GmbH | Munster | Germany | Participant |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Kairos GmbH | Bochum | Germany | Participant |
| Karlsruher Institut Fuer Technologie | Karlsruhe | Germany | Participant |
| Klinikum Der Ludwig-Maximilians-Universitat Munchen | Munchen | Germany | Third party |
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Participant |
| Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eV | Munchen | Germany | Participant |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Novamechanics Monoprosopi Ike | Piraeus | Greece | Participant |
| Fundacio Centre De Regulacio Genomica | Barcelona | Spain | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon | Madrid | Spain | Participant |
| Hospital Clinic De Barcelona | Barcelona | Spain | Third party |
| Institut Du Cerveau Et De La Moelle Epiniere | Paris | France | Participant |
| Alma Mater Studiorum - Universita Di Bologna | Bologna | Italy | Participant |
| Associazione Oasi Maria SS. Onlus | Troina | Italy | Participant |
| Universita Degli Studi Di Brescia | Brescia | Italy | Participant |
| Universita Degli Studi Di Cagliari | Cagliari | Italy | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Oslo Universitetssykehus Hf | Oslo | Norway | Participant |
| Universitetet I Oslo | Oslo | Norway | Third party |
| Goeteborgs Universitet | Goeteborg | Sweden | Participant |
| Cardiff University | Cardiff | United Kingdom | Associatedpartner |
| King's College London | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI